Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Jansen

Showing results (191-200 of 254) with videos related to

Pageof 26
Sort By:
The Lancet. Infectious Diseases|September 6, 2020
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trialJudith Absalon, Nathan Segall, Stan L Block, et al.
Journal of Clinical Microbiology|August 28, 2015
Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate CollectionsC Hal Jones, Naglaa Mohamed, Eduardo Rojas, et al.
Immunology Letters|December 25, 2012
Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in miceJ Erik Johnson, Lisa K McNeil, Shakuntala Megati, et al.
Vaccine|December 6, 2016
Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 studyRobert W Frenck, C Buddy Creech, Eric A Sheldon, et al.
Vaccine|July 13, 2004
Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy womenKenneth H Fife, Cosette M Wheeler, Laura A Koutsky, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2020
Qualification and Clinical Validation of an Immunodiagnostic Assay for Detecting 11 Additional Streptococcus pneumoniae Serotype-specific Polysaccharides in Human UrineWarren V Kalina, Victor Souza, Kangjian Wu, et al.
The New England Journal of Medicine|March 8, 2021
Neutralizing Activity of BNT162b2-Elicited SerumYang Liu, Jianying Liu, Hongjie Xia, et al.
The New England Journal of Medicine|April 27, 2022
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in PregnancyEric A F Simões, Kimberly J Center, Alan T N Tita, et al.
The Lancet. Infectious Diseases|June 16, 2025
Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1/2 randomised controlled trialBabalwa Jongihlati, Nathan Segall, Stanley L Block, et al.
The New England Journal of Medicine|June 22, 2022
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge StudyBeate Schmoele-Thoma, Agnieszka M Zareba, Qin Jiang, et al.
Pageof 26

Showing results (191-200 of 254) with videos related to

Sort By:
Pageof 26
The Lancet. Infectious Diseases|September 6, 2020
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trialJudith Absalon, Nathan Segall, Stan L Block, et al.
Journal of Clinical Microbiology|August 28, 2015
Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate CollectionsC Hal Jones, Naglaa Mohamed, Eduardo Rojas, et al.
Immunology Letters|December 25, 2012
Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in miceJ Erik Johnson, Lisa K McNeil, Shakuntala Megati, et al.
Vaccine|December 6, 2016
Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 studyRobert W Frenck, C Buddy Creech, Eric A Sheldon, et al.
Vaccine|July 13, 2004
Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy womenKenneth H Fife, Cosette M Wheeler, Laura A Koutsky, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2020
Qualification and Clinical Validation of an Immunodiagnostic Assay for Detecting 11 Additional Streptococcus pneumoniae Serotype-specific Polysaccharides in Human UrineWarren V Kalina, Victor Souza, Kangjian Wu, et al.
The New England Journal of Medicine|March 8, 2021
Neutralizing Activity of BNT162b2-Elicited SerumYang Liu, Jianying Liu, Hongjie Xia, et al.
The New England Journal of Medicine|April 27, 2022
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in PregnancyEric A F Simões, Kimberly J Center, Alan T N Tita, et al.
The Lancet. Infectious Diseases|June 16, 2025
Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1/2 randomised controlled trialBabalwa Jongihlati, Nathan Segall, Stanley L Block, et al.
The New England Journal of Medicine|June 22, 2022
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge StudyBeate Schmoele-Thoma, Agnieszka M Zareba, Qin Jiang, et al.
Pageof 26